FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定

2020-01-17 不详 MedSci原创

在美国食品和药物管理局(FDA)已经授予Arena Pharmaceuticals公司的β3肾上腺素能受体(ADRR)拮抗剂APD418的快速通道指定,用于治疗代偿性心脏衰竭(DHF)。

在美国食品和药物管理局(FDA)已经授予Arena Pharmaceuticals公司的β3肾上腺素能受体(ADRR)拮抗剂APD418的快速通道指定,用于治疗代偿性心脏衰竭(DHF)。

代偿性心力衰竭(DHF)的特征表现为呼吸困难、腿或脚肿胀和疲劳。该公司表示,这是65岁以上患者住院的主要原因,在过去的20年中,很少有新药物被批准用于DHF。

Arena高级副总裁兼首席医疗官Chris Cabell说:"预计到2025年,美国将有大约1千万DHF病人到医院就诊,而且几乎没有可行的治疗选择,我们相信APD418可能会对这些病人产生重大影响。"

APD418是β3 -肾上腺素能受体(ADRR)的选择性拮抗剂,旨在改善心脏收缩力,同时对心率、血压和心肌耗氧量影响最小,因此有可能避免与当前的正性肌疗法相关的不良事件。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2020-04-09 wumeihua88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1779989, encodeId=793e1e79989ba, content=<a href='/topic/show?id=89e02631e9' target=_blank style='color:#2F92EE;'>#APD418#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2631, encryptionId=89e02631e9, topicName=APD418)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Apr 09 06:40:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043660, encodeId=0f95204366083, content=<a href='/topic/show?id=b46f1921993' target=_blank style='color:#2F92EE;'>#β3-肾上腺素能受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19219, encryptionId=b46f1921993, topicName=β3-肾上腺素能受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Jun 13 09:40:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895198, encodeId=448f1895198e8, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Sep 17 11:40:00 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808855, encodeId=62fd180885561, content=<a href='/topic/show?id=946d82443e5' target=_blank style='color:#2F92EE;'>#肾上腺素能受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82443, encryptionId=946d82443e5, topicName=肾上腺素能受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Oct 09 09:40:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284933, encodeId=6242128493320, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52084, encryptionId=775e52084ac, topicName=快速通道指定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88a5514460, createdName=qidongfanjian, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511748, encodeId=d9a31511e4833, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sun Jan 19 12:40:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]

相关资讯

默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查

默沙东宣布已向FDA成功完成PARP抑制剂Lynparza(olaparib)的补充新药申请,并被授予优先审查,与贝伐单抗(Genentech出售,阿瓦斯汀(Avastin))用于晚期卵巢癌。

Nektar的阿片类镇痛药惨遭FDA专家小组全票否决

因担心滥用药物和缺乏数据,Nektar Therapeutics的阿片类镇痛药惨遭FDA全票拒绝通过。

FDA批准抗CTLA-4抗体ONC-392的IDN

OncoImmune制药公司近日宣布,其新一代抗CTLA-4抗体ONC-392的研究性新药申请(IND)已获得美国FDA批准。

FDA授予Molgradex突破性疗法认定,用于治疗自身免疫性肺泡蛋白沉着症

Savara制药公司宣布,美国FDA已授予Molgradex突破性疗法认定,Molgradex是一种重组人粒细胞-巨噬细胞集落刺激因子(GM-CSF)的吸入制剂,用于治疗自身免疫性肺泡蛋白沉着症(aPAP)。

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗,展开优先审查

FDA已经开始对未接受过治疗且没有EGFR或ALK突变的NSCLC患者进行PD-1抑制剂Opdivo(nivolumab)联合BMS低剂量CTLA4抑制剂Yervoy(ipilimumab)进行优先审查,并于5月15日前作出判决。